Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Key facts

Study ID
NCT03127267
Run by
AB Science
People needed
495
Starts
2021-02-02
Expected to finish
2027-12-01
Last updated by the study team
2025-09-12

Who can join

Age: 18 and older, up to 81. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.